Latest revenue
$71.1M
as of 2026-03-31
Latest net income
$-24.8M
as of 2026-03-31
Net margin
-34.9%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $485.9M
- Enterprise value
- $485.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $31.04
- 52-wk low
- $13.46
- Beta
- —
- Shares out
- 28.4M
5-year trend
What this company does
Item 1. Business. Overview We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. Mission and Vision Founded in 2011, Fulgent began with two simple ideas:…
AI summary unavailable — showing raw filing excerpt
Generated from FLGT's filing dated 2026-02-27
Key risks
Item 1A. Risk Factors. Summary of Risk Factors Investing in our common stock involves a high degree of risk. Before making any investment decision with respect to our common stock, you should carefully consider the risks described below, together with the other risk factors set forth in this Item 1A, all other information included in this report, and the other reports and documents filed by us with the SEC. The risk factors described below are a summary of the principal risk factors associated with an investment in us. Cybersecurity Risks •Actual or attempted security incidents or breaches, loss of data, or other disruptions could expose us to material liability and materially and adversely…
AI summary unavailable — showing raw filing excerpt
Generated from FLGT's filing dated 2026-02-27
Profitability
Gross margin
40.6%
7.2%Operating margin
-28.2%
8.3%Net margin
-18.8%
24.5%Return on equity
-5.4%
44.4%Return on assets
-5.0%
42.4%Leverage
Debt / equity
0.09×
19.3%Debt / assets
8.4%
17.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $71.1M | -3.2% | $-24.8M | -115.3% | -34.9% |
Q4 2025 2025-12-31 | $83.3M | +9.3% | $-23.4M | -297.7% | -28.1% |
Q3 2025 2025-09-30 | $84.1M | +17.2% | $-6.6M | +54.9% | -7.9% |
Q2 2025 2025-06-30 | $81.8M | +15.2% | $-19.0M | -117.6% | -23.2% |
Q1 2025 2025-03-31 | $73.5M | +13.9% | $-11.5M | +14.4% | -15.7% |
Q4 2024 2024-12-31 | $76.2M | — | $-5.9M | — | -7.7% |
Q3 2024 2024-09-30 | $71.7M | -15.3% | $-14.6M | -11.8% | -20.4% |
Q2 2024 2024-06-30 | $71.0M | +4.7% | $-8.7M | +22.4% | -12.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on FLGT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$673.3K
Net activity
−$673.3K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns FLGT
Institutional value
$121.5M
Total shares held
8.9M
Distinct holders
82
-95 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2.8M | $44.1M | -187.7K (-6.3%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 880.1K | $14.0M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 671.7K | $10.7M | -217.3K (-24.4%) | Trimmed |
| 4 | JPMORGAN CHASE & CO | 460.4K | $7.2M | +210.2K (+84.1%) | Added |
| 5 | DEUTSCHE BANK AG\ | 325.4K | $5.2M | -113.5K (-25.9%) | Trimmed |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 302.6K | $4.8M | -72.3K (-19.3%) | Trimmed |
| 7 | UBS Group AG | 240.8K | $3.8M | +157.2K (+188.1%) | Added |
| 8 | Peapod Lane Capital LLC | 220.6K | $3.5M | +54.8K (+33.1%) | Added |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 215.9K | $3.4M | — | New |
| 10 | Allianz Asset Management GmbH | 181.9K | $2.9M | +48.4K (+36.3%) | Added |
| 11 | WELLS FARGO & COMPANY/MN | 147.1K | $2.3M | +26.4K (+21.8%) | Added |
| 12 | VANGUARD FIDUCIARY TRUST CO | 129.5K | $2.1M | — | New |
| 13 | Nuveen, LLC | 104.0K | $1.7M | -227.6K (-68.6%) | Trimmed |
| 14 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 101.3K | $1.6M | +1.0K (+1.0%) | Added |
| 15 | Russell Investments Group, Ltd. | 93.5K | $1.5M | +15.4K (+19.8%) | Added |
| 16 | Bank of New York Mellon Corp | 76.3K | $1.2M | -8.5K (-10.0%) | Trimmed |
| 17 | SEI INVESTMENTS CO | 74.2K | $1.2M | -320 (-0.4%) | Trimmed |
| 18 | Y-Intercept (Hong Kong) Ltd | 67.7K | $1.1M | — | New |
| 19 | HSBC HOLDINGS PLC | 65.2K | $1.0M | -38.9K (-37.4%) | Trimmed |
| 20 | Invesco Ltd. | 57.0K | $906.0K | -5.0K (-8.1%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once FLGT's latest filing finishes processing.